Skip to main content

Recent Sentinel Activity

This recent activity feed provides a list of the last 90 days of Sentinel activity across assessments, publications & presentations, projects, events, etc.

RSS Feed

URL Title Category Date Recent Activity
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/ustekinumab-dispensing-patterns-descriptive-analysis Ustekinumab Dispensing Patterns: A Descriptive Analysis Analyses
Ustekinumab Dispensing Patterns: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/methods/covid-19-pregnancy-study-implementation COVID-19 Pregnancy Study Implementation Methods, Data, & Tools
COVID-19 Pregnancy Study Implementation
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-individuals-sentinel-distributed-database Counts of Individuals in the Sentinel Distributed Database Modular Programs
Counts of Individuals in the Sentinel Distributed Database
Modular Programs
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2016 Duration of Follow Up for New Molecular Entities Approved in 2016 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2016
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2014-and Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2010-2012 Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2008-and Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2005-2006 Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2011 Duration of Follow Up for New Molecular Entities Approved in 2011 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2011
Analyses
https://www.sentinelinitiative.org/methods-data-tools/methods/making-medicaid-data-more-accessible-through-common-data-models-and-fhir Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs Methods, Data, & Tools
Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/racial-differences-covid-19-outcomes-2020-2021 Racial Differences in COVID-19 Outcomes (2020-2021) Assessments
Racial Differences in COVID-19 Outcomes (2020-2021)
Assessments
https://www.sentinelinitiative.org/news-events/publications-presentations/validation-diagnosis-codes-identify-hospitalized-covid-19 Validation of Diagnosis Codes to Identify Hospitalized COVID-19 Patients in Health Care Claims Data Publications and Presentations
Validation of Diagnosis Codes to Identify Hospitalized COVID-19 Patients in Health Care Claims Data
Publications and Presentations
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/thromboembolic-stroke-algorithm-defined-1 Thromboembolic Stroke Algorithm Defined in "Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 and Older: An IPTW Analysis" Methods, Data, & Tools
Thromboembolic Stroke Algorithm Defined in "Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 and Older: An IPTW Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/gastrointestinal-bleeding-algorithm-defined-0 Gastrointestinal Bleeding Algorithm Defined in "Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 and Older: An IPTW Analysis" Methods, Data, & Tools
Gastrointestinal Bleeding Algorithm Defined in "Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 and Older: An IPTW Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/major-extracranial-bleeding-algorithm-defined-1 Major Extracranial Bleeding Algorithm Defined in "Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 and Older: An IPTW Analysis" Methods, Data, & Tools
Major Extracranial Bleeding Algorithm Defined in "Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 and Older: An IPTW Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/intracranial-hemorrhage-algorithm-defined-1 Intracranial Hemorrhage Algorithm Defined in "Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 and Older: An IPTW Analysis" Methods, Data, & Tools
Intracranial Hemorrhage Algorithm Defined in "Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 and Older: An IPTW Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/methods/improving-capture-race-and-ethnicity-data-sentinel Improving Capture of Race and Ethnicity Data in Sentinel Methods, Data, & Tools
Improving Capture of Race and Ethnicity Data in Sentinel
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/incident-and-prevalent-use-loop-diuretics-descriptive Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis Analyses
Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/engage-sentinel/quarterly-newsletter Quarterly Newsletter Spotlight
Quarterly Newsletter
Spotlight
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/estimated-prevalence-glomerular-diseases-descriptive Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis Analyses
Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/estimated-prevalence-glomerular-diseases-updated-descriptive Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis Analyses
Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/thromboembolic-stroke-major-extracranial-bleeding-0 Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 or Older: An Inverse Probability of Treatment Weighting (IPTW) Analysis Analyses
Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 or Older: An Inverse Probability of Treatment Weighting (IPTW) Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/serious-infection-following-ustekinumab-use-patients-crohn-s Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis Analyses
Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/methods/approaches-handling-partially-observed-confounder-data-electronic-health Approaches to Handling Partially Observed Confounder Data From Electronic Health Records (EHR) In Non-randomized Studies of Medication Outcomes Methods, Data, & Tools
Approaches to Handling Partially Observed Confounder Data From Electronic Health Records (EHR) In Non-randomized Studies of Medication Outcomes
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/bamlanivimab-bamlanivimab-and-etesevimab-and-casirivimab Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis Analyses
Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/count-and-duration-follow-new-onset-cancer-updated Count and Duration of Follow-up of New-Onset Cancer: An Updated Descriptive Analysis Analyses
Count and Duration of Follow-up of New-Onset Cancer: An Updated Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-monoclonal-antibodies-mabs-under-emergency-use Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis Analyses
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/hospitalization-and-anaphylaxis-following-monoclonal Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis Analyses
Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/new-onset-cancer-cases-fda-s-sentinel-system-large New-Onset Cancer Cases in FDA’s Sentinel System: A Large Distributed System of US Electronic Healthcare Data Publications and Presentations
New-Onset Cancer Cases in FDA’s Sentinel System: A Large Distributed System of US Electronic Healthcare Data
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/differences-covid-19-testing-positivity-hospitalization-and Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis Analyses
Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-monoclonal-antibodies-mabs-under-emergency-use-0 Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis Analyses
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/switching-patterns-mixed-amphetamine-salt-products-fda-s Switching Patterns of Mixed Amphetamine Salt Products in the FDA’s Sentinel Distributed Database Publications and Presentations
Switching Patterns of Mixed Amphetamine Salt Products in the FDA’s Sentinel Distributed Database
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/racial-differences-us-covid-19-positivity-hospitalization Racial Differences in U.S. COVID-19 Positivity, Hospitalization, and Mortality Spotlight
Racial Differences in U.S. COVID-19 Positivity, Hospitalization, and Mortality
Spotlight
https://www.sentinelinitiative.org/news-events/publications-presentations/characterizing-pediatric-members-sentinel-distributed Characterizing Pediatric Members in the Sentinel Distributed Database Publications and Presentations
Characterizing Pediatric Members in the Sentinel Distributed Database
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/describing-prenatal-exposures-and-evaluating-maternal-and Describing Prenatal Exposures and Evaluating Maternal and Infant Outcomes in Sentinel Publications and Presentations
Describing Prenatal Exposures and Evaluating Maternal and Infant Outcomes in Sentinel
Publications and Presentations
https://www.sentinelinitiative.org/methods-data-tools/methods/onboarding-commercial-electronic-health-record-ehr-data-partners Onboarding of Commercial Electronic Health Record (EHR) Data Partners Methods, Data, & Tools
Onboarding of Commercial Electronic Health Record (EHR) Data Partners
Methods, Data, & Tools
https://www.sentinelinitiative.org/news-events/publications-presentations/data-driven-automated-classification-algorithms-acute-health Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease Publications and Presentations
Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-ozempic-use-patients-type-2 Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis Analyses
Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/valganciclovir-use-children-congenital-cytomegalovirus Valganciclovir Use in Children with Congenital Cytomegalovirus Infection: Chart Review Methods, Data, & Tools
Valganciclovir Use in Children with Congenital Cytomegalovirus Infection: Chart Review
Methods, Data, & Tools
https://www.sentinelinitiative.org/news-events/publications-presentations/improving-data-capture-race-and-ethnicity Improving Data Capture of Race and Ethnicity Publications and Presentations
Improving Data Capture of Race and Ethnicity
Publications and Presentations
https://www.sentinelinitiative.org/methods-data-tools/sentinel-common-data-model/sentinel-common-components-sas-program-package Sentinel Common Components SAS® Program Package Common Data Model
Sentinel Common Components SAS® Program Package
Common Data Model
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-zarxio-use-updated-signal Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis Analyses
Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/active-surveillance-medical-product-use-fda-s-sentinel Active Surveillance of Medical Product Use in the FDA’s Sentinel System: A Focus on Pediatric Populations Publications and Presentations
Active Surveillance of Medical Product Use in the FDA’s Sentinel System: A Focus on Pediatric Populations
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/brand-generic-switching-patterns-among-advair-diskus-users Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis Analyses
Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-and-switching-patterns-inhaled Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis Analyses
Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/ischemic-colitis-following-alosetron-use-descriptive Ischemic Colitis Following Alosetron Use: A Descriptive Analysis Analyses
Ischemic Colitis Following Alosetron Use: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/r-package-perform-routine-structural-missing-data An R Package to Perform Routine Structural Missing Data Investigations in Real-World Data Publications and Presentations
An R Package to Perform Routine Structural Missing Data Investigations in Real-World Data
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/switching-patterns-immediate-release-forms-generic-mixed Switching Patterns of Immediate-Release Forms of Generic Mixed Amphetamine Salts Products Among Privately and Publicly Insured Individuals Aged 15-64 Years in the United States, 2013-2019 Publications and Presentations
Switching Patterns of Immediate-Release Forms of Generic Mixed Amphetamine Salts Products Among Privately and Publicly Insured Individuals Aged 15-64 Years in the United States, 2013-2019
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/signal-detection-and-refinement-activities-within-fda-s-0 Signal Detection and Refinement Activities within FDA’s Sentinel System Publications and Presentations
Signal Detection and Refinement Activities within FDA’s Sentinel System
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/alosetron-and-eluxadoline-use-descriptive-analysis Alosetron and Eluxadoline Use: A Descriptive Analysis Analyses
Alosetron and Eluxadoline Use: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/dupixent-dupilumab-utilization-patterns-descriptive-analysis Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis Analyses
Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/treatment-and-care-received-children-hospitalized-covid-19 Treatment and Care Received by Children Hospitalized with COVID-19 in a Large Hospital Network in the United States, February 2020 to September 2021 Publications and Presentations
Treatment and Care Received by Children Hospitalized with COVID-19 in a Large Hospital Network in the United States, February 2020 to September 2021
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-cannabis-derived-product-users-trinetx-four Characterization of Cannabis-Derived Product Users in TriNetX: Four Descriptive Analyses Analyses
Characterization of Cannabis-Derived Product Users in TriNetX: Four Descriptive Analyses
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-beta-blockers-pediatric-population-descriptive Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis Analyses
Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-beta-blockers-pediatric-population-updated Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis Analyses
Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/improving-data-capture-race-and-ethnicity-food-and-drug Improving Data Capture of Race and Ethnicity for the Food and Drug Administration Sentinel Database: A Narrative Review Publications and Presentations
Improving Data Capture of Race and Ethnicity for the Food and Drug Administration Sentinel Database: A Narrative Review
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-and-switching-patterns-mixed-amphetamine-salt Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis Analyses
Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/utilization-beta-blockers-among-pediatric-population-united Utilization of Beta-blockers Among the Pediatric Population in the United States: A Study in the FDA’s Sentinel System from 2008 to 2022 Publications and Presentations
Utilization of Beta-blockers Among the Pediatric Population in the United States: A Study in the FDA’s Sentinel System from 2008 to 2022
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/association-between-race-and-covid-19-outcomes-united-states Association Between Race and COVID-19 Outcomes in the United States (2020-2021) Publications and Presentations
Association Between Race and COVID-19 Outcomes in the United States (2020-2021)
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/racial-and-ethnic-differences-treatment-hospitalized-and Racial and Ethnic Differences in Treatment of Hospitalized and Critical COVID-19, January 2021 - April 2022 Publications and Presentations
Racial and Ethnic Differences in Treatment of Hospitalized and Critical COVID-19, January 2021 - April 2022
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/variation-mother-infant-linkage-rates-jurisdiction-us Variation in Mother-Infant Linkage Rates by Jurisdiction in U.S. Medicaid Data Publications and Presentations
Variation in Mother-Infant Linkage Rates by Jurisdiction in U.S. Medicaid Data
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/principled-approaches-handle-partially-observed-confounder Principled Approaches to Handle Partially Observed Confounder Data from Electronic Health Records: A Plasmode Simulation Study Publications and Presentations
Principled Approaches to Handle Partially Observed Confounder Data from Electronic Health Records: A Plasmode Simulation Study
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/expanding-capabilities-unapproved-cannabis-derived-product Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022 Publications and Presentations
Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/exploring-use-electronic-health-records-ehr-data-active Exploring the Use of Electronic Health Records (EHR) Data for Active Safety Surveillance of Epidiolex in PCORnet, July 1, 2018 - July 1, 2022 Publications and Presentations
Exploring the Use of Electronic Health Records (EHR) Data for Active Safety Surveillance of Epidiolex in PCORnet, July 1, 2018 - July 1, 2022
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-products-development-pregnancy-safety-study Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Analyses
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-products-development-pregnancy-safety-study-0 Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis Analyses
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/proton-pump-inhibitors Proton Pump Inhibitors & COVID-19 Hospitalization and Severe COVID-19 Studies
Proton Pump Inhibitors & COVID-19 Hospitalization and Severe COVID-19
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/covid-19-hospitalization-and-severe-covid-19-infection-0 COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis Analyses
COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/covid-19-hospitalization-algorithm-defined-covid-19 COVID-19 Hospitalization Algorithm Defined in COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis Methods, Data, & Tools
COVID-19 Hospitalization Algorithm Defined in COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis
Methods, Data, & Tools
https://www.sentinelinitiative.org/news-events/publications-presentations/assessing-risk-intentional-self-harm-montelukast-users-0 Assessing the Risk of Intentional Self-Harm in Montelukast Users: An Observational Study in the Sentinel System Using ICD-10 Coding Publications and Presentations
Assessing the Risk of Intentional Self-Harm in Montelukast Users: An Observational Study in the Sentinel System Using ICD-10 Coding
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-non-cardiac-congenital-malformations-following Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis Analyses
Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/non-cardiac-congenital-malformations-algorithm-defined Non-Cardiac Congenital Malformations Algorithm Defined in "Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis" Methods, Data, & Tools
Non-Cardiac Congenital Malformations Algorithm Defined in "Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/methods/monitoring-safety-and-effectiveness-covid-19-therapeutics-aim-1-protocol Monitoring of Safety and Effectiveness of COVID-19 Therapeutics: Aim 1 Protocol Development Study Protocols & Surveillance Plan
Monitoring of Safety and Effectiveness of COVID-19 Therapeutics: Aim 1 Protocol Development
Study Protocols & Surveillance Plan
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-cannabis-derived-product-users-national Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis Analyses
Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/assessing-risk-intentional-self-harm-montelukast-users Assessing the Risk of Intentional Self-Harm in Montelukast Users: An Updated Sentinel System Analysis Using ICD-10 Coding Publications and Presentations
Assessing the Risk of Intentional Self-Harm in Montelukast Users: An Updated Sentinel System Analysis Using ICD-10 Coding
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/data-driven-automated-classification-algorithms-acute-0 Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease Publications and Presentations
Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/bimzelx-bimekizumab-bkzx Assessment of ARIA Sufficiency: Bimzelx (bimekizumab-bkzx) Sufficiency Assessments
Assessment of ARIA Sufficiency: Bimzelx (bimekizumab-bkzx)
Sufficiency Assessments
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2024-sentinel-innovation-and-methods-seminar-series 2024 Sentinel Innovation and Methods Seminar Series Sentinel Initiative Events
2024 Sentinel Innovation and Methods Seminar Series
Sentinel Initiative Events
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/covid-19-chart-validation-covid-19-severity-algorithm COVID-19 Chart Validation of COVID-19 Severity Algorithm Methods, Data, & Tools
COVID-19 Chart Validation of COVID-19 Severity Algorithm
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/mixed-amphetamine-salts-immediate-release-tablet-use Mixed Amphetamine Salts Immediate-Release Tablet Use: A Descriptive Analysis Analyses
Mixed Amphetamine Salts Immediate-Release Tablet Use: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/publications-presentations/smdi-r-package-perform-structural-missing-data smdi: An R Package to Perform Structural Missing Data Investigations on Partially Observed Confounders in Real-world Evidence Studies Publications and Presentations
smdi: An R Package to Perform Structural Missing Data Investigations on Partially Observed Confounders in Real-world Evidence Studies
Publications and Presentations
https://www.sentinelinitiative.org/news-events/publications-presentations/risk-arterial-and-venous-thrombotic-events-among-patients Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States Publications and Presentations
Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/olumiant-baricitinib-and-actemra-tocilizumab Olumiant (Baricitinib) and Actemra (Tocilizumab) & Emergency Use Authorization (EUA) Utilization Studies
Olumiant (Baricitinib) and Actemra (Tocilizumab) & Emergency Use Authorization (EUA) Utilization
Studies
https://www.sentinelinitiative.org/studies/drugs/provigil-modafinil-and-nuvigil-armodafinil-0 Provigil (Modafinil) and Nuvigil (Armodafinil) & Congenital Cardiac and Non-Cardiac Malformations Studies
Provigil (Modafinil) and Nuvigil (Armodafinil) & Congenital Cardiac and Non-Cardiac Malformations
Studies
https://www.sentinelinitiative.org/studies/drugs/dupixent-dupilumab-0 Dupixent (Dupilumab) & Indications for Use Studies
Dupixent (Dupilumab) & Indications for Use
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-and-characteristics-long-acting-injectable Counts and Characteristics of Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis Analyses
Counts and Characteristics of Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/process-guide-inferential-studies-using-healthcare-data A PRocess guide for INferential studies using healthcare data from routine ClinIcal Practice to evaLuate causal Effects of Drugs (PRINCIPLED) Sentinel Initiative Events
A PRocess guide for INferential studies using healthcare data from routine ClinIcal Practice to evaLuate causal Effects of Drugs (PRINCIPLED)
Sentinel Initiative Events
https://www.sentinelinitiative.org/studies/drugs/brintellix-vortioxetine-and-brilinta-ticragelor Brintellix (Vortioxetine) and Brilinta (Ticragelor) & Medication Errors Studies
Brintellix (Vortioxetine) and Brilinta (Ticragelor) & Medication Errors
Studies
https://www.sentinelinitiative.org/methods-data-tools/methods/maintaining-and-expanding-reach-sentinel-ehr-and-claims-network-di8 Maintaining and Expanding the Reach of the Sentinel EHR and Claims Network (DI8) Methods, Data, & Tools
Maintaining and Expanding the Reach of the Sentinel EHR and Claims Network (DI8)
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/mixed-amphetamine-salts Mixed Amphetamine Salts & Switching Patterns Studies
Mixed Amphetamine Salts & Switching Patterns
Studies
https://www.sentinelinitiative.org/studies/drugs/rinvoq-upadacitinib Rinvoq (Upadacitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, and Thrombotic Stroke Studies
Rinvoq (Upadacitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, and Thrombotic Stroke
Studies
https://www.sentinelinitiative.org/studies/drugs/glomerular-diseases Glomerular Diseases & Prevalence Studies
Glomerular Diseases & Prevalence
Studies
https://www.sentinelinitiative.org/studies/drugs/lotronex-alosetron Lotronex (Alosetron) & Ischemic Colitis Studies
Lotronex (Alosetron) & Ischemic Colitis
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/occurrence-stroke-intracranial-hemorrhage-and-bleeding Occurrence of Stroke, Intracranial Hemorrhage, and Bleeding Outcomes Following Direct Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Descriptive Analysis Analyses
Occurrence of Stroke, Intracranial Hemorrhage, and Bleeding Outcomes Following Direct Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/capture-long-covid-trinetx-descriptive-analysis Capture of Long COVID in TriNetX: A Descriptive Analysis Analyses
Capture of Long COVID in TriNetX: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/chronic-conditions Chronic Conditions & Duration of Follow-Up Studies
Chronic Conditions & Duration of Follow-Up
Studies
https://www.sentinelinitiative.org/studies/drugs/covid-19-patients COVID-19 Patients & Long COVID Studies
COVID-19 Patients & Long COVID
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/ustekinumab-and-comparator-treatment-utilization-and Ustekinumab and Comparator Treatment Utilization and Pneumonia Outcomes in Patients with Crohn's Disease or Ulcerative Colitis: An Updated Descriptive Analysis Analyses
Ustekinumab and Comparator Treatment Utilization and Pneumonia Outcomes in Patients with Crohn's Disease or Ulcerative Colitis: An Updated Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-gimoti-metoclopramide-nasal-spray Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: A Descriptive Analysis Analyses
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-gimoti-metoclopramide-nasal-spray-0 Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: An Updated Descriptive Analysis Analyses
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: An Updated Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/racial-and-ethnic-differences-clinical-characteristics Racial and Ethnic Differences in the Clinical Characteristics of Patients with Various Stages of COVID-19: A Descriptive Analysis Analyses
Racial and Ethnic Differences in the Clinical Characteristics of Patients with Various Stages of COVID-19: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-and-coding-patterns-long-acting-injectable Utilization and Coding Patterns of Long-Acting Injectable Antipsychotics (LAIA): A Descriptive Analysis Analyses
Utilization and Coding Patterns of Long-Acting Injectable Antipsychotics (LAIA): A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/covid-19-outcomes COVID-19 Patients & Racial and Ethnic Differences Studies
COVID-19 Patients & Racial and Ethnic Differences
Studies
https://www.sentinelinitiative.org/studies/drugs/long-acting-injectable-antipsychotics Long-Acting Injectable Antipsychotics & Mortality Studies
Long-Acting Injectable Antipsychotics & Mortality
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/arterial-and-venous-thrombotic-events-patients-covid-19 Arterial and Venous Thrombotic Events in Patients with COVID-19 in Inpatient and Ambulatory Settings: A Descriptive Analysis Analyses
Arterial and Venous Thrombotic Events in Patients with COVID-19 in Inpatient and Ambulatory Settings: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/xenpozyme-olipudase-alfa-rpcp Assessment of ARIA Sufficiency: Xenpozyme (olipudase alfa-rpcp) Sufficiency Assessments
Assessment of ARIA Sufficiency: Xenpozyme (olipudase alfa-rpcp)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/rystiggo-rozanolixizumab-noli Assessment of ARIA Sufficiency: Rystiggo (rozanolixizumab-noli) Sufficiency Assessments
Assessment of ARIA Sufficiency: Rystiggo (rozanolixizumab-noli)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/statins-tumor-necrosis-factor-tnf-alpha-inhibitors-granulocyte-colony-stimulating Statins, Tumor Necrosis Factor (TNF) Alpha Inhibitors, Granulocyte Colony Stimulating Factors, Intravenous (IV) Iron, Beta Blockers, and Angiotensin-Converting Enzyme (ACE) Inhibitors & Utilization Studies
Statins, Tumor Necrosis Factor (TNF) Alpha Inhibitors, Granulocyte Colony Stimulating Factors, Intravenous (IV) Iron, Beta Blockers, and Angiotensin-Converting Enzyme (ACE) Inhibitors & Utilization
Studies
https://www.sentinelinitiative.org/studies/drugs/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-ii-receptor-blockers Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs) & Signal Identification Studies
Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs) & Signal Identification
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-following-montelukast-use-patients Intentional Self-Harm Following Montelukast Use in Patients with Asthma: An Updated Analysis Using ICD-10-CM Coding Analyses
Intentional Self-Harm Following Montelukast Use in Patients with Asthma: An Updated Analysis Using ICD-10-CM Coding
Analyses
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/intentional-self-harm-algorithm-defined-intentional-0 Intentional Self-Harm Algorithm Defined in "Intentional Self-Harm Following Montelukast Use in Patients with Asthma: An Updated Analysis Using ICD-10-CM Coding" Methods, Data, & Tools
Intentional Self-Harm Algorithm Defined in "Intentional Self-Harm Following Montelukast Use in Patients with Asthma: An Updated Analysis Using ICD-10-CM Coding"
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/singulair-montelukast-0 Singulair (Montelukast) & Intentional Self-Harm Studies
Singulair (Montelukast) & Intentional Self-Harm
Studies
https://www.sentinelinitiative.org/news-events/publications-presentations/targeted-learning-undersmoothed-lasso-propensity-score-model Targeted Learning with an Undersmoothed Lasso Propensity Score Model for Large-Scale Covariate Adjustment in Healthcare Database Studies Publications and Presentations
Targeted Learning with an Undersmoothed Lasso Propensity Score Model for Large-Scale Covariate Adjustment in Healthcare Database Studies
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/count-and-duration-follow-new-onset-cancer-descriptive Count and Duration of Follow-up of New-Onset Cancer: A Descriptive Analysis Analyses
Count and Duration of Follow-up of New-Onset Cancer: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/new-onset-cancer New-Onset Cancer & Duration of Follow-up Studies
New-Onset Cancer & Duration of Follow-up
Studies
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/data-driven-phenotyping-algorithms-acute-health-conditions Data-driven Phenotyping Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Sentinel Initiative Events
Data-driven Phenotyping Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19
Sentinel Initiative Events
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/vyvgart-hytrulo-efgartigimod-alfa-and Assessment of ARIA Sufficiency: Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Sufficiency Assessments
Assessment of ARIA Sufficiency: Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/exxua-gepirone-hydrochloride Assessment of ARIA Sufficiency: Exxua (gepirone hydrochloride) Sufficiency Assessments
Assessment of ARIA Sufficiency: Exxua (gepirone hydrochloride)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/fluticasone-salmeterol Fluticasone and Salmeterol & Brand to Generic Switching Studies
Fluticasone and Salmeterol & Brand to Generic Switching
Studies
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/zilbrysq-zilucoplan Assessment of ARIA Sufficiency: Zilbrysq (zilucoplan) Sufficiency Assessments
Assessment of ARIA Sufficiency: Zilbrysq (zilucoplan)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/mounjaro-tirzepatide Assessment of ARIA Sufficiency: Mounjaro (tirzepatide) Sufficiency Assessments
Assessment of ARIA Sufficiency: Mounjaro (tirzepatide)
Sufficiency Assessments
https://www.sentinelinitiative.org/news-events/publications-presentations/validity-inpatient-electronic-health-record-based-measures Validity of Inpatient Electronic Health Record-Based Measures of Oxygen-Related Therapy in the United States: Lessons Applicable for Studying COVID-19 Endpoints Publications and Presentations
Validity of Inpatient Electronic Health Record-Based Measures of Oxygen-Related Therapy in the United States: Lessons Applicable for Studying COVID-19 Endpoints
Publications and Presentations
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-users-new-molecular-entities-approved-2021 Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis Analyses
Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system Sentinel Routine Querying System Methods, Data, & Tools
Sentinel Routine Querying System
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system-reporting-tool Sentinel Routine Querying System Reporting Tool Methods, Data, & Tools
Sentinel Routine Querying System Reporting Tool
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-loop-diuretics-descriptive-analysis Utilization of Loop Diuretics: A Descriptive Analysis Analyses
Utilization of Loop Diuretics: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/litfulo-ritlecitinib Litfulo (Ritlecitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism & Stroke Studies
Litfulo (Ritlecitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism & Stroke
Studies
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/jesduvroq-daprodustat Assessment of ARIA Sufficiency: Jesduvroq (daprodustat) Sufficiency Assessments
Assessment of ARIA Sufficiency: Jesduvroq (daprodustat)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-products-over-time-development-pregnancy-safety Utilization of Products Over Time for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Analyses
Utilization of Products Over Time for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/opportunities-and-challenges-use-large-language-models Opportunities and Challenges in the use of Large Language Models for Post-Marketing Surveillance of Medical Products Sentinel Initiative Events
Opportunities and Challenges in the use of Large Language Models for Post-Marketing Surveillance of Medical Products
Sentinel Initiative Events
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/validation-hospitalized-covid-19-diagnosis-detected-claims Validation of Hospitalized COVID-19 Diagnosis Detected from Claims-Based Algorithms: A Descriptive Analysis Analyses
Validation of Hospitalized COVID-19 Diagnosis Detected from Claims-Based Algorithms: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/hydrochlorothiazide-1 Hydrochlorothiazide & Utilization Studies
Hydrochlorothiazide & Utilization
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/hydrochlorothiazide-use-following-labeling-update-include-0 Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Interrupted Time Series Analysis Analyses
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Interrupted Time Series Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/cannabinoid-products Cannabinoid Products & Cohort Characterization Studies
Cannabinoid Products & Cohort Characterization
Studies
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/rezdiffra-resmetirom Assessment of ARIA Sufficiency: Rezdiffra (resmetirom) Sufficiency Assessments
Assessment of ARIA Sufficiency: Rezdiffra (resmetirom)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/vafseo-vadadustat Assessment of ARIA Sufficiency: Vafseo (vadadustat) Sufficiency Assessments
Assessment of ARIA Sufficiency: Vafseo (vadadustat)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/entyvio-vedolizumab-and-tysabri-natalizumab Entyvio (Vedolizumab) and Tysabri (Natalizumab) & Interstitial Lung Disease Studies
Entyvio (Vedolizumab) and Tysabri (Natalizumab) & Interstitial Lung Disease
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/interstitial-lung-disease-ild-patients-inflammatory-bowel Interstitial Lung Disease (ILD) in Patients with Inflammatory Bowel Disease (IBD) and Following Vedolizumab or Natalizumab Initiation: A Descriptive Analysis Analyses
Interstitial Lung Disease (ILD) in Patients with Inflammatory Bowel Disease (IBD) and Following Vedolizumab or Natalizumab Initiation: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/interstitial-lung-disease-ild-rates-patients-inflammatory Interstitial Lung Disease (ILD) Rates in Patients with Inflammatory Bowel Disease (IBD) and Following IBD Advanced Therapy: A Descriptive Analysis Analyses
Interstitial Lung Disease (ILD) Rates in Patients with Inflammatory Bowel Disease (IBD) and Following IBD Advanced Therapy: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/interstitial-lung-disease-algorithm-defined Interstitial Lung Disease Algorithm Defined in "Interstitial Lung Disease (ILD) in Patients with Inflammatory Bowel Disease (IBD) and Following Vedolizumab or Natalizumab Initiation: A Descriptive Analysis" Methods, Data, & Tools
Interstitial Lung Disease Algorithm Defined in "Interstitial Lung Disease (ILD) in Patients with Inflammatory Bowel Disease (IBD) and Following Vedolizumab or Natalizumab Initiation: A Descriptive Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/interstitial-lung-disease-algorithm-defined-0 Interstitial Lung Disease Algorithm Defined in "Interstitial Lung Disease (ILD) Rates in Patients with Inflammatory Bowel Disease (IBD) and Following IBD Advanced Therapy: A Descriptive Analysis" Methods, Data, & Tools
Interstitial Lung Disease Algorithm Defined in "Interstitial Lung Disease (ILD) Rates in Patients with Inflammatory Bowel Disease (IBD) and Following IBD Advanced Therapy: A Descriptive Analysis"
Methods, Data, & Tools
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/tryvio-aprocitentan Assessment of ARIA Sufficiency: Tryvio (aprocitentan) Sufficiency Assessments
Assessment of ARIA Sufficiency: Tryvio (aprocitentan)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2007 Duration of Follow Up for New Molecular Entities Approved in 2007: A Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved in 2007: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/voydeya-danicopan Assessment of ARIA Sufficiency: Voydeya (danicopan) Sufficiency Assessments
Assessment of ARIA Sufficiency: Voydeya (danicopan)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/new-molecular-entities-nmes New Molecular Entities (NMEs) & Utilization Characterization Studies
New Molecular Entities (NMEs) & Utilization Characterization
Studies
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/duvyzat-givinostat Assessment of ARIA Sufficiency: Duvyzat (givinostat) Sufficiency Assessments
Assessment of ARIA Sufficiency: Duvyzat (givinostat)
Sufficiency Assessments
https://www.sentinelinitiative.org/studies/drugs/brexafemme-ibrexafungerp Brexafemme (Ibrexafungerp) & Use in Pregnancy Studies
Brexafemme (Ibrexafungerp) & Use in Pregnancy
Studies
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-ibrexafungerp-pregnant-patients-updated Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis in TriNetX Analyses
Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis in TriNetX
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/concomitant-use-medications-drug-drug-interactions Concomitant Use of Medications with Drug-Drug Interactions with Nirmatrelvir and Ritonavir Among Patients Treated with Nirmatrelvir and Ritonavir or Patients with COVID-19: A Descriptive Analysis Analyses
Concomitant Use of Medications with Drug-Drug Interactions with Nirmatrelvir and Ritonavir Among Patients Treated with Nirmatrelvir and Ritonavir or Patients with COVID-19: A Descriptive Analysis
Analyses
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-beta-blockers-pediatric-population-follow Utilization of Beta Blockers in the Pediatric Population: A Follow Up Updated Descriptive Analysis Analyses
Utilization of Beta Blockers in the Pediatric Population: A Follow Up Updated Descriptive Analysis
Analyses